Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.

ABSTRACT: Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.

SUBMITTER: Wu MY 

PROVIDER: S-EPMC10113515 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature